SNPs associated with rubella virus-specific neutralizing antibody responses in Caucasians.

aGenotypes for the Rochester cohort, presented as homozygous major allele/heterozygous/homozygous minor allele. N indicates the number of subjects with the specific genotype.
bImmune outcomes for the Rochester cohort, presented as median neutralizing antibody titer in NT50± IQR (inter-quartile range), as measured by the sICNA assay.
cOrdinal p-value for analysis in the Rochester cohort only, after adjusting for gender, assay batch effect, quartiles of age at enrollment, immunization age, time since last immunization to enrollment, and race-specific population stratification eigenvectors.
dGenotypes for the San Diego cohort, presented as homozygous major allele/heterozygous/homozygous minor allele. N indicates the number of subjects with the specific genotype.
eImmune outcomes for the San Diego cohort, presented as median neutralizing antibody titer in NT50± IQR (inter-quartile range), as measured by the sICNA assay.
fOrdinal p-value for analysis in the San Diego cohort only, after adjusting for gender, assay batch effect, quartiles of age at enrollment, immunization age, time since last immunization to enrollment, and race-specific population stratification eigenvectors.
gMeta-analysis p-value after adjusting for gender, assay batch effect, quartiles of age at enrollment, immunization age, time since last immunization to enrollment, and race-specific population stratification eigenvectors; pooled estimate from the meta analysis showing the magnitude and direction of the estimated effect on the immune measure; homogeneity test p-value estimating the homogeneity between the two cohorts. Only SNPs with p-value below 0.05 in the meta-analysis and homogeneity test p-value above 0.1 are presented.